Mohr U, Weissleder R
Department of Radiology-Center for Molecular Imaging Research (CIMR), Massachusetts General Hospital, Boston, USA.
Z Lymphol. 1996 Jun;20(1):15-20.
The main problem in current lymph node imaging is the lack of reliable criteria for differential diagnosis between benign and malignant nodes, the main criterion being size. To reliably opacify all lymph nodes in the body, an intravenous contrast agent is therefore necessary. Two new contrast agents for MRI seem promising: lymphotropic iron oxides and Gadolinium DTPA-PGM. After intravenous administration these agents accumulate in phagocytic cells of normal lymph nodes but are excluded from nodes in which phagocytic activity is replaced. While iron oxides are already in clinical studies, GD-DTPA-PGM is in preclinical studies. Both agents seem to significantly improve the differential diagnosis between benign and malignant lymph nodes irrespective of size.
当前淋巴结成像的主要问题是缺乏鉴别良性和恶性淋巴结的可靠标准，主要标准是大小。因此，为了可靠地使体内所有淋巴结显影，静脉注射造影剂是必要的。两种用于磁共振成像（MRI）的新型造影剂似乎很有前景：亲淋巴氧化铁和钆喷酸葡甲胺（Gadolinium DTPA-PGM）。静脉给药后，这些造影剂会在正常淋巴结的吞噬细胞中蓄积，但不会进入吞噬活性被取代的淋巴结。虽然氧化铁已进入临床研究阶段，钆喷酸葡甲胺仍处于临床前研究阶段。这两种造影剂似乎都能显著改善无论大小的良性和恶性淋巴结之间的鉴别诊断。
